GCG and Hypoglycemia: Since native incretin is rapidly inactivated by dipeptidyl peptidase-4 (DPP-4), DPP-resistant GLP-1 receptor agonists (GLP-1RAs) and DPP-4 inhibitors have been developed and now widely used for the treatment of diabetic patients as incretin-based agents because of their superiority to classical insulinotropic agents, such as sulfonylureas and glinides from the standpoint of low risks for hypoglycemia and body weight gain [13,14,15].